| A multisite preregistered paradigmatic test of the ego-depletion effect KD Vohs, BJ Schmeichel, S Lohmann, QF Gronau, AJ Finley, ... Psychological Science 32 (10), 1566-1581, 2021 | 162 | 2021 |
| Two definitions of waiting well. K Sweeny, CA Reynolds, A Falkenstein, SE Andrews, MD Dooley Emotion 16 (1), 129, 2016 | 69 | 2016 |
| Is waiting the hardest part? Comparing the emotional experiences of awaiting and receiving bad news K Sweeny, A Falkenstein Personality and Social Psychology Bulletin 41 (11), 1551-1559, 2015 | 62 | 2015 |
| Characteristics and correlates of word use in physician-patient communication A Falkenstein, B Tran, D Ludi, A Molkara, H Nguyen, A Tabuenca, ... Annals of Behavioral Medicine 50 (5), 664-677, 2016 | 33 | 2016 |
| Even optimists get the blues: Interindividual consistency in the tendency to brace for the worst K Sweeny, A Falkenstein Journal of personality 85 (6), 807-816, 2017 | 13 | 2017 |
| The role of gender in worry and efforts to cope during stressful waiting periods K Sweeny, V Kwan, A Falkenstein Sex Roles 81 (11), 765-778, 2019 | 11 | 2019 |
| Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma T Mark, A Falkenstein, J Kish Future Oncology 18 (5), 553-564, 2022 | 9 | 2022 |
| Fluctuations in future outlooks: Unrealistic optimism and pessimism in outcome predictions. JA Shepperd, A Falkenstein, K Sweeny The Guilford Press, 2018 | 6 | 2018 |
| Real-world outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) treated with luspatercept: an evaluation of US clinical practice utilization and treatment … S Mukherjee, C Brown-Bickerstaff, A McBride, A Gajra, D Gentile, ... Blood 140 (Supplement 1), 944-946, 2022 | 4 | 2022 |
| Monitoring and management of interstitial lung disease/pneumonitis among patients with metastatic breast cancer treated with trastuzumab deruxtecan. JK Kish, S Mehta, J Kwong, C Lam, A Falkenstein, C Brown-Bickerstaff, ... Journal of Clinical Oncology 40 (16_suppl), 1036-1036, 2022 | 3 | 2022 |
| Lower-risk myelodysplastic syndromes: erythropoiesis-stimulating agent treatment approaches and outcomes in the United States KMZ Savill, A Gajra, K Price, JK Kish, C Brown-Bickerstaff, A Falkenstein, ... Blood 138, 4657, 2021 | 3 | 2021 |
| Focusing on future forecasts: A comprehensive examination of performance expectations AR Falkenstein UC Riverside, 2018 | 2 | 2018 |
| P733: TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN ROUTINE CLINICAL PRACTICE IN THE UNITED STATES S Mukherjee, C Brown-Bickerstaff, D Huggar, A Falkenstein, AY Makinde, ... HemaSphere 7 (S3), e648138a, 2023 | 1 | 2023 |
| Real-world erythropoiesis-stimulating agent (ESA) treatment patterns and outcomes among US patients with lower-risk myelodysplastic syndromes (LR-MDS). S Mukherjee, KMZ Savill, A Gajra, JK Kish, C Brown-Bickerstaff, D Gentile, ... Journal of Clinical Oncology 40 (16_suppl), e19065-e19065, 2022 | 1 | 2022 |
| Waiting for health news A Falkenstein, MD Dooley, K Sweeny The Wiley encyclopedia of health psychology, 781-788, 2020 | 1 | 2020 |
| Loving-Kindness Meditation and Prosocial Construct Activation AR Falkenstein | 1 | 2013 |
| Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysis S Mukherjee, C Brown‐Bickerstaff, A Falkenstein, AY Makinde, E Bland, ... HemaSphere 8 (1), e38, 2024 | | 2024 |
| MDS-065 Treatment Patterns and Transfusion Outcomes Among Erythropoietin-Stimulating Agent (ESA)-Naïve Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving … S Mukherjee, C Brown-Bickerstaff, D Huggar, A Falkenstein, AY Makinde, ... Clinical Lymphoma Myeloma and Leukemia 23, S352-S353, 2023 | | 2023 |
| POSTER: MDS-065 Treatment Patterns and Transfusion Outcomes Among Erythropoietin-Stimulating Agent (ESA)-Naïve Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS … S Mukherjee, C Brown-Bickerstaff, D Huggar, A Falkenstein, AY Makinde, ... Clinical Lymphoma Myeloma and Leukemia 23, S180, 2023 | | 2023 |
| Hematologic and transfusion outcomes in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept: Real-world assessment in the community … S Mukherjee, C Brown-Bickerstaff, A Falkenstein, AY Makinde, E Bland, ... Journal of Clinical Oncology 41 (16_suppl), 7057-7057, 2023 | | 2023 |
